Literature DB >> 32671618

The Potent PDE10A Inhibitor MP-10 (PF-2545920) Suppresses Microglial Activation in LPS-Induced Neuroinflammation and MPTP-Induced Parkinson's Disease Mouse Models.

Do-Yeon Kim1, Jin-Sun Park1, Yea-Hyun Leem1, Jung-Eun Park1, Hee-Sun Kim2,3.   

Abstract

MP-10 (PF-2545920) is a selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme highly enriched in the striatum, nucleus accumbens, olfactory tubercle, and substantia nigra. The therapeutic effect of MP-10 has been reported in psychiatric and neurodegenerative disorders such as schizophrenia, depression, and Huntington's disease. However, the effect of MP-10 in Parkinson's disease (PD) has not been reported to date. In this study, we examined the effect of MP-10 in neuroinflammation and PD mouse models. MP-10 inhibited nitric oxide, tumor necrosis factor alpha, and interleukin (IL)-6 production, while it promoted IL-10 production in lipopolysaccharide (LPS)-stimulated BV2 microglial cells. Subsequent western blot and reverse transcription polymerase chain reaction analyses showed that MP-10 reduced the mRNA and protein levels of inducible nitric oxide synthase, cyclooxygenase-2, proinflammatory cytokines, and matrix metalloproteinase-3, -8, and - 9 in LPS-stimulated BV2 cells. Further mechanistic studies revealed that MP-10 exerts anti-inflammatory effects by inhibiting the phosphorylation of c-Jun N-terminal kinase and Akt, reducing the activity of nuclear factor-kappa B/activator protein-1, and upregulating the nuclear factor erythroid 2-related factor 2/antioxidant response element and protein kinase A/cAMP response element-binding protein signaling pathways. The anti-inflammatory effect of MP-10 was confirmed in vivo. Specifically, MP-10 inhibited microglial activation and proinflammatory gene expression in the brains of LPS-injected mice. Moreover, MP-10 rescued behavioral deficits and recovered dopaminergic neuronal cell death in the brains of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced PD mice. MP-10 also reduced microglial activation in this PD mouse model. These data collectively suggest that MP-10 may have therapeutic potential in PD and other neuroinflammatory disorders. Graphical Abstract.

Entities:  

Keywords:  MP-10; Microglia; Molecular mechanism; Neuroinflammation; Neuroprotection; Parkinson’s disease

Mesh:

Substances:

Year:  2020        PMID: 32671618     DOI: 10.1007/s11481-020-09943-6

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  33 in total

1.  An immortalized cell line expresses properties of activated microglial cells.

Authors:  V Bocchini; R Mazzolla; R Barluzzi; E Blasi; P Sick; H Kettenmann
Journal:  J Neurosci Res       Date:  1992-04       Impact factor: 4.164

Review 2.  Microglia biology in health and disease.

Authors:  Gwenn A Garden; Thomas Möller
Journal:  J Neuroimmune Pharmacol       Date:  2006-03-25       Impact factor: 4.147

Review 3.  Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.

Authors:  Louise M Collins; André Toulouse; Thomas J Connor; Yvonne M Nolan
Journal:  Neuropharmacology       Date:  2012-02-15       Impact factor: 5.250

Review 4.  Mechanisms underlying inflammation in neurodegeneration.

Authors:  Christopher K Glass; Kaoru Saijo; Beate Winner; Maria Carolina Marchetto; Fred H Gage
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 5.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.

Authors:  Karen Bedard; Karl-Heinz Krause
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

6.  High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.

Authors:  S Cristina; R Zangaglia; F Mancini; E Martignoni; G Nappi; Claudio Pacchetti
Journal:  Clin Neuropharmacol       Date:  2003 May-Jun       Impact factor: 1.592

7.  Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach.

Authors:  A Bertolino; D Crippa; S di Dio; K Fichte; G Musmeci; V Porro; V Rapisarda; M Sastre-y-Hernández; M Schratzer
Journal:  Int Clin Psychopharmacol       Date:  1988-07       Impact factor: 1.659

8.  Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.

Authors:  M Giorgi; V D'Angelo; Z Esposito; V Nuccetelli; R Sorge; A Martorana; A Stefani; G Bernardi; G Sancesario
Journal:  Eur J Neurosci       Date:  2008-08-20       Impact factor: 3.386

9.  Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines.

Authors:  Mousumi Ghosh; Yong Xu; Damien D Pearse
Journal:  J Neuroinflammation       Date:  2016-01-13       Impact factor: 8.322

Review 10.  Neuroinflammation and M2 microglia: the good, the bad, and the inflamed.

Authors:  Jonathan D Cherry; John A Olschowka; M Kerry O'Banion
Journal:  J Neuroinflammation       Date:  2014-06-03       Impact factor: 8.322

View more
  3 in total

1.  Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury.

Authors:  Carolyn Tallon; Silvia Picciolini; Seung-Wan Yoo; Ajit G Thomas; Arindom Pal; Jesse Alt; Cristiano Carlomagno; Alice Gualerzi; Rana Rais; Norman J Haughey; Marzia Bedoni; Barbara S Slusher
Journal:  Biochem Pharmacol       Date:  2021-10-20       Impact factor: 5.858

2.  Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination.

Authors:  Zhiwei Xiao; Huiyi Wei; Yi Xu; Ahmed Haider; Junjie Wei; Shiyu Yuan; Jian Rong; Chunyu Zhao; Guocong Li; Weibin Zhang; Huangcan Chen; Yuefeng Li; Lingling Zhang; Jiyun Sun; Shaojuan Zhang; Hai-Bin Luo; Sen Yan; Qijun Cai; Lu Hou; Chao Che; Steven H Liang; Lu Wang
Journal:  Acta Pharm Sin B       Date:  2021-11-17       Impact factor: 14.903

3.  Inhibition of PDE10A-Rescued TBI-Induced Neuroinflammation and Apoptosis through the cAMP/PKA/NLRP3 Pathway.

Authors:  Jin Huang; Dang Tang; Yiqiang Cao; Yonggang Wang; Jiang Long; Lin Wei; Hai Song
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-12       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.